BrainStorm Therapeutics won the Servier Discovery Award
Selected for the California Life Sciences FAST California program as the Servier Discovery Award winner.
Brain Storm Therapeutics A precision neuroscience therapeutic discovery company
Accelerating and de-risking the discovery of breakthrough medicines for complex neurological disorders.
Precision medicine approach · Patient inspired · ML/AI-powered
Recognition
- NSF-funded Featured in the National Science Foundation showcase Read more
- Featured by NVIDIA “Making brain waves” on the NVIDIA blog Read more
- Servier Discovery Award CLS FAST California, Fall 2025 cohort Read more
- People’s Choice Award The AI Conference Startup Showdown Read more
- Top 3 at Bits in Bio San Diego TechBio Startup Showcase Read more
Recognition coming soon.
Transforming neuroscience drug discovery and development
Utilizing patient biology, biomarker-based screening, and advanced data analytics to de-risk clinical translation.
Precision medicine approach
Genetically validated targets that drive human disease biology.
Experienced team
BrainStorm is led by an experienced team of neuroscientists, stem cell biologists, and drug developers.
Proprietary technology
We de-risk clinical translation using patient biology, biomarker-based screening, and advanced data analytics.
AI/ML powered
Leveraging deep learning and network medicine.
CNS drug discovery needs a paradigm shift
Widely used preclinical models underperform at predicting drug efficacy and safety, and the late introduction of human biology in the R&D process leads to high failure and cost.
Why current CNS drug discovery fails
- Lack of animal and cell culture models that accurately predict human efficacy.
- Underlying heterogeneity of disease processes arising from a combination of genetic, environmental, and lifestyle factors.
- It is unlikely that a single drug engaging one target will be effective for substantial segments of the patient population.
- Limited understanding of the impact of target biology on the complex network of intracellular and intercellular disease processes.
Patient-derived brain organoids are a powerful platform for CNS drug discovery
“Human-first” patient-derived brain organoid platform bridging the translational valley of death.
Our proprietary platform leverages human patient iPSC-derived models of brain disease and the computational tools of deep learning and network medicine to identify therapeutic candidates that halt, prevent, or reverse synaptic network dysfunction and neurodegeneration.
Brain organoids
Living, self-organized 3D structures derived from human iPSCs that mimic human brain tissue and exhibit highly synchronized and spontaneous synaptic network activity.
Biomarker-based screening endpoints
Capture robust and reproducible, clinically translatable disease phenotypes that are amenable to multiple screening applications and high-content imaging.
De-risking clinical translation
Accelerate the generation of human efficacy and safety data early in the R&D process, resulting in safer and more effective clinical candidates.
FDA Modernization Act 2.0
Recognizes that human brain organoids provide a more accurate and reliable evaluation of drug efficacy and safety, reducing the reliance on animal work.
Currently focused on drug discovery for Parkinson’s disease
Human PD patient-derived midbrain organoids recapitulate key elements of PD pathophysiology, including dopamine neuron degeneration and synaptic dysfunction.
- 01
PD pathophysiology
Midbrain organoids from PD patients.
- 02
Genetic entry points
Autophagy/lysosomal and mitochondrial/oxidative stress pathways.
- 03
Underlying disease processes
Phenotypic screening with clinically translatable endpoints.
- 04
Better clinical trials
Molecular signatures to refine endpoints and patient selection.
From our founder
“The brain is the last frontier in modern biology.”
Dr. Robert Fremeau founded BrainStorm Therapeutics to discover and develop breakthrough medicines to transform the lives of the millions of patients suffering from devastating neurological disorders.
Before BrainStorm, he was Chief Scientific Officer at Vyant Bio, where his team discovered repurposing candidates for Rett syndrome that are advancing to a Phase 2 clinical trial funded by the Department of Defense. He was previously a Scientific Director in neuroscience at Amgen and a faculty member at Duke University and UCSF.
Dr. Robert Fremeau Founder and CEO, BrainStorm Therapeutics
News & publications
Awards, press features and talks from the BrainStorm team.
CSO Maya Gosztyla won the People’s Choice Award at The AI Conference Startup Showdown
Co-founder Dr. Maya Gosztyla took home the People’s Choice Award at The AI Conference 2025.
CEO Robert Fremeau presented at the Plug and Play Tech Center
Robert Fremeau pitched BrainStorm’s AI-powered precision medicine platform at a Plug and Play pitch event.
Get in touch
Talk to us about our precision neuroscience platform, our Parkinson’s disease program, or working with the BrainStorm team.